… to assess the efficacy and safety of sacubitril/valsartan in Japanese HFrEF … , sacubitril/valsartan
has been demonstrated to be safe, well tolerated and beneficial in Japanese patients …

… of sacubitril-valsartan was selected for patients with acute decompensated heart failure
with a reduced ejection … 932 HFrEF patients verified the effectiveness of sacubitril-valsartan. …

… with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the …
to evaluate the efficacy and safety of sacubitril/valsartan treatment for patients with HFpEF. …

… the pharmacological mechanisms of sacubitril/valsartan, including the reduction … efficacy of
sacubitril/valsartan in HF patients with reduced ejection fraction (HFrEF) or preserved ejection …

… Regarding efficacy/effectiveness, we focused on the indication as per European Medicines
… , that is, heart failure with reduced ejection fraction (HFrEF). Regarding safety and tolerability, …

… Sac/val was recommended as a new treatment option for patients with heart failure with
reduced ejection fraction (HFrEF) in the 2016 European Society for Cardiology guidelines (ESC) […

… sacubitril/valsartan have suggested possible clinical benefit among patients with heart failure
with preserved ejection … study the efficacy and safety of sacubitril/valsartan among patients …

… NYHA class I–III heart failure and with reduced ejection fraction ≤ 40% Sacubitril-valsartan
vs. … Fan 2020 [24] Randomised clinical trial 120 HF HF Sacubitril/valsartan vs. valsartan …

… This meta-analysis suggests that sacubitril-valsartan may be an effective and safe strategy
with which to improve the clinical symptoms and reduce HF hospitalisation in HFmEF and …

… to assess the tolerability, safety, and efficacy of sacubitril/valsartan compared with valsartan
in patients with advanced chronic heart failure with a reduced ejection fraction and recent …